Radiopharmaceuticals Expert Joins Clarity as Chief Scientific Officer
Sydney, Australia 13 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Jeffrey Norenberg as Chief Scientific Officer (CSO), effective immediately. Dr Norenberg has more…